[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Impact of Malignancy on Vacular Outcomes in Patients with Atrial Fibrillation",
    "section": "",
    "text": "Reference Papers:\n\nElbadawi et al. 2017\nEl-Rayes et al. 2025"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Impact of Malignancy on Vacular Outcomes in Patients with Atrial Fibrillation",
    "section": "",
    "text": "Reference Papers:\n\nElbadawi et al. 2017\nEl-Rayes et al. 2025"
  },
  {
    "objectID": "quarto/index.html#preamble-1",
    "href": "quarto/index.html#preamble-1",
    "title": "Impact of Malignancy on Vacular Outcomes in Patients with Atrial Fibrillation",
    "section": "Preamble:",
    "text": "Preamble:\n\nStudy Objective: To examine the impact of malignancy on outcomes among admissions with atrial fibrillation.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020. The NIS is part of the Healthcare Cost and Utilization Project (HCUP) and provides a stratified sample of inpatient discharges from U.S. community hospitals across all payers.\nCohort Definition: Patients were included if they met the following criteria\n\nAge ≥18 years\nHad a diagnosis of atrial fibrillation and cancer\nPatients undergoing catheter ablation were excluded\n\nPrimary Outcomes:\n\nAcute ischemic stroke\nPulmonary embolism\nVenous thromboembolism\nMajor bleeding\n\nSecondary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nCovariates for Adjustment: All models adjusted for the following\n\nDemographics: Age, sex, race, income, insurance, urbanicity, hospital region, hospital bedsize, hospital location, and teaching status.\nMedical History: Hypertension, diabetes mellitus, obesity, hyperlipidemia, coronary artery disease, peripheral vascular disease, heart failure, dementia, chronic kidney disease, chronic pulmonary disease, obstructive sleep apnea, liver disease, valvular heart disease, valvular heart disease, alcohol abuse, smoker, prior stroke, prior cardiac surgery, and type of cancer.\nComorbidities: Elixhauser comorbidity index.\n\nStatistical Methods:\n\nUnivariable Analysis:\n\nCategorical variables: Compared using Pearson’s chi-square test with Rao & Scott adjustment\nContinuous variables: Analyzed using the design-based Kruskal–Wallis test, a non-parametric alternative suitable for survey-weighted data\n\nMultivariable Analysis:\n\nBinary outcomes (e.g., mortality): Survey-weighted logistic regression using the quasibinomial family\nContinuous outcomes (e.g., LOS, hospital charges): Survey-weighted linear regression using the gaussian family\nResults reported as adjusted odds ratios (aORs) or beta coefficients with 95% confidence intervals\n\n\nSoftware: All statistical analyses were performed using the R Statistical Language (Version 4.5.0; R Foundation for Statistical Computing, Vienna, Austria), incorporating survey-weighted procedures via the survey package to account for the complex sampling design of NIS."
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Impact of Malignancy on Vacular Outcomes in Patients with Atrial Fibrillation",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 27,0151\nAtrial Fibrillation without Cancer\nN = 24,2751\nAtrial Fibrillation with Cancer\nN = 2,7401\np-value2\n\n\n\n\nAge, y\n75 (12)\n75 (12)\n75 (11)\n&gt;0.9\n\n\nSex\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n12,385 (46%)\n11,350 (47%)\n1,035 (38%)\n\n\n\n\n    Male\n14,630 (54%)\n12,925 (53%)\n1,705 (62%)\n\n\n\n\nRace\n\n\n\n\n\n\n0.3\n\n\n    White\n21,480 (81%)\n19,240 (80%)\n2,240 (83%)\n\n\n\n\n    Asian or Pacific Islander\n750 (2.8%)\n700 (2.9%)\n50 (1.8%)\n\n\n\n\n    Black\n1,995 (7.5%)\n1,785 (7.5%)\n210 (7.8%)\n\n\n\n\n    Hispanic\n1,695 (6.4%)\n1,570 (6.6%)\n125 (4.6%)\n\n\n\n\n    Native American\n160 (0.6%)\n150 (0.6%)\n10 (0.4%)\n\n\n\n\n    Other\n550 (2.1%)\n480 (2.0%)\n70 (2.6%)\n\n\n\n\nCharlson comorbidity index\n3.40 (2.26)\n3.14 (2.05)\n5.73 (2.70)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n0.003\n\n\n    $1 - $51,999\n6,320 (24%)\n5,775 (24%)\n545 (20%)\n\n\n\n\n    $52,000 - $65,999\n6,930 (26%)\n6,285 (26%)\n645 (24%)\n\n\n\n\n    $66,000 - $87,999\n6,790 (26%)\n6,115 (26%)\n675 (25%)\n\n\n\n\n    $88,000 or more\n6,565 (25%)\n5,705 (24%)\n860 (32%)\n\n\n\n\nExpected primary payer\n\n\n\n\n\n\n0.012\n\n\n    Private\n3,195 (12%)\n2,835 (12%)\n360 (13%)\n\n\n\n\n    Medicaid\n1,595 (5.9%)\n1,510 (6.2%)\n85 (3.1%)\n\n\n\n\n    Medicare\n21,650 (80%)\n19,400 (80%)\n2,250 (82%)\n\n\n\n\n    Other\n550 (2.0%)\n510 (2.1%)\n40 (1.5%)\n\n\n\n\nHospital region\n\n\n\n\n\n\n0.8\n\n\n    Midwest\n5,845 (22%)\n5,290 (22%)\n555 (20%)\n\n\n\n\n    Northeast\n4,095 (15%)\n3,640 (15%)\n455 (17%)\n\n\n\n\n    South\n8,715 (32%)\n7,840 (32%)\n875 (32%)\n\n\n\n\n    West\n8,360 (31%)\n7,505 (31%)\n855 (31%)\n\n\n\n\nLocation of patient’s residence\n\n\n\n\n\n\n0.079\n\n\n    Central metro ≥1 million\n7,105 (26%)\n6,390 (26%)\n715 (26%)\n\n\n\n\n    Fringe metro ≥1 million\n7,455 (28%)\n6,600 (27%)\n855 (31%)\n\n\n\n\n    Metro 250,000-999,999\n5,310 (20%)\n4,765 (20%)\n545 (20%)\n\n\n\n\n    Metro 50,000-249,999\n2,935 (11%)\n2,720 (11%)\n215 (7.8%)\n\n\n\n\n    Micropolitan\n2,380 (8.8%)\n2,110 (8.7%)\n270 (9.9%)\n\n\n\n\n    Other\n1,735 (6.4%)\n1,595 (6.6%)\n140 (5.1%)\n\n\n\n\nHypertension\n23,350 (86%)\n21,140 (87%)\n2,210 (81%)\n&lt;0.001\n\n\nDiabetes mellitus\n10,440 (39%)\n9,580 (39%)\n860 (31%)\n&lt;0.001\n\n\nHyperlipidemia\n15,450 (57%)\n14,015 (58%)\n1,435 (52%)\n0.018\n\n\nCoronary artery disease\n11,570 (43%)\n10,570 (44%)\n1,000 (36%)\n0.001\n\n\nPeripheral vascular disease\n4,320 (16%)\n3,865 (16%)\n455 (17%)\n0.7\n\n\nHeart failure\n15,440 (57%)\n14,080 (58%)\n1,360 (50%)\n&lt;0.001\n\n\nChronic kidney disease\n10,145 (38%)\n9,180 (38%)\n965 (35%)\n0.2\n\n\nChronic obstructive pulmonary disease\n9,320 (34%)\n8,360 (34%)\n960 (35%)\n0.8\n\n\nValvular heart disease\n6,345 (23%)\n5,810 (24%)\n535 (20%)\n0.028\n\n\nLiver disease\n1,725 (6.4%)\n1,590 (6.5%)\n135 (4.9%)\n0.14\n\n\nObstructive sleep apnea\n3,980 (15%)\n3,600 (15%)\n380 (14%)\n0.6\n\n\nAnemia\n2,110 (7.8%)\n1,875 (7.7%)\n235 (8.6%)\n0.5\n\n\nAlcohol use disorder\n9,650 (36%)\n8,635 (36%)\n1,015 (37%)\n0.5\n\n\nObesity\n5,685 (21%)\n5,220 (22%)\n465 (17%)\n0.022\n\n\nPrior stroke\n4,500 (17%)\n4,150 (17%)\n350 (13%)\n0.008\n\n\nPrior cardiac surgery\n3,845 (14%)\n3,545 (15%)\n300 (11%)\n0.028\n\n\nSmoker\n135 (0.5%)\n125 (0.5%)\n10 (0.4%)\n0.6\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nAtrial Fibrillation without Cancer\nN = 24,2751\nAtrial Fibrillation with Cancer\nN = 2,7401\np-value2\n\n\n\n\nDied during hospitalization\n1,110 (4.6%)\n200 (7.3%)\n0.004\n\n\nAcute ischemic stroke\n40 (0.2%)\n0 (0%)\n0.3\n\n\nVenours thromboembolism\n705 (2.9%)\n185 (6.8%)\n&lt;0.001\n\n\nMajor bleeding\n4,245 (17%)\n510 (19%)\n0.5\n\n\nLength of stay (days)\n5.9 (6.6)\n7.3 (8.5)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n84,037 (123,725)\n105,558 (174,779)\n&lt;0.001\n\n\n\n1 n (%); Mean (SD)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Impact of Malignancy on Vacular Outcomes in Patients with Atrial Fibrillation",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nCategories\n\n\n\n\n\n\n\n\n    Atrial Fibrillation without Cancer\n—\n—\n\n\n\n\n    Atrial Fibrillation with Cancer\n1.25\n0.83, 1.89\n0.3\n\n\nAge, y\n1.04\n1.02, 1.05\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.10\n0.81, 1.49\n0.5\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n2.17\n1.01, 4.67\n0.047\n\n\n    Black\n0.80\n0.45, 1.44\n0.5\n\n\n    Hispanic\n1.60\n0.92, 2.81\n0.10\n\n\n    Native American\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Other\n0.23\n0.03, 1.62\n0.14\n\n\nElixhauser comorbidity index\n1.56\n1.41, 1.72\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.62\n0.41, 0.95\n0.029\n\n\n    $66,000 - $87,999\n0.80\n0.52, 1.24\n0.3\n\n\n    $88,000 or more\n0.74\n0.46, 1.20\n0.2\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.74\n0.66, 4.61\n0.3\n\n\n    Medicare\n1.55\n0.85, 2.82\n0.2\n\n\n    Other\n4.58\n1.85, 11.3\n&lt;0.001\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n1.06\n0.66, 1.70\n0.8\n\n\n    South\n0.95\n0.65, 1.39\n0.8\n\n\n    West\n1.04\n0.65, 1.66\n0.9\n\n\nLocation of patient’s residence\n\n\n\n\n\n\n\n\n    Central metro ≥1 million\n—\n—\n\n\n\n\n    Fringe metro ≥1 million\n1.16\n0.77, 1.74\n0.5\n\n\n    Metro 250,000-999,999\n0.86\n0.55, 1.36\n0.5\n\n\n    Metro 50,000-249,999\n0.88\n0.49, 1.59\n0.7\n\n\n    Micropolitan\n0.96\n0.51, 1.78\n0.9\n\n\n    Other\n1.27\n0.73, 2.21\n0.4\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.53\n0.34, 0.84\n0.007\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.78\n0.55, 1.09\n0.14\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.74\n0.54, 1.01\n0.058\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.72, 1.36\n&gt;0.9\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.36\n0.21, 0.62\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.73\n0.53, 1.01\n0.059\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.80\n0.58, 1.11\n0.2\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.82\n0.59, 1.12\n0.2\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.57\n0.39, 0.83\n0.003\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.44\n0.87, 2.39\n0.2\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.48\n0.26, 0.90\n0.023\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.32\n0.17, 0.62\n&lt;0.001\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.59\n0.42, 0.83\n0.002\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.44\n0.28, 0.69\n&lt;0.001\n\n\nPrior stroke\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.63\n0.40, 1.02\n0.059\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.51\n0.29, 0.90\n0.019\n\n\nSmoker\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.60\n0.39, 17.4\n0.3\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nAcute Ischemic stroke:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nCategories\n\n\n\n\n\n\n\n\n    Atrial Fibrillation without Cancer\n—\n—\n\n\n\n\n    Atrial Fibrillation with Cancer\n16.9\n0.02, 12,795\n0.4\n\n\nAge, y\n0.95\n0.69, 1.31\n0.8\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n205\n2.23, 18,828\n0.021\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Black\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Hispanic\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Native American\n0.09\n0.00, 56.7\n0.5\n\n\n    Other\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nElixhauser comorbidity index\n2.30\n0.94, 5.62\n0.067\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n296,443,696\n67,977, 1,292,770,825,689\n&lt;0.001\n\n\n    $66,000 - $87,999\n101,936,125,808\n603,746, 17,210,841,351,616,434\n&lt;0.001\n\n\n    $88,000 or more\n838,901,399,489\n16,756,086, 41,999,997,173,604,224\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Medicare\n0.05\n0.00, 192\n0.5\n\n\n    Other\n0.00\n0.00, 0.01\n0.006\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n347\n10.7, 11,250\n&lt;0.001\n\n\n    South\n1.35\n0.07, 25.9\n0.8\n\n\n    West\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nLocation of patient’s residence\n\n\n\n\n\n\n\n\n    Central metro ≥1 million\n—\n—\n\n\n\n\n    Fringe metro ≥1 million\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Metro 250,000-999,999\n0.13\n0.01, 1.77\n0.13\n\n\n    Metro 50,000-249,999\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Micropolitan\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n    Other\n747\n0.48, 1,163,518\n0.078\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.00\n0.00, 0.48\n0.029\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n31.4\n0.96, 1,029\n0.053\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.05\n0.16, 6.76\n&gt;0.9\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.76\n0.12, 63.9\n0.5\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n15.8\n0.02, 10,686\n0.4\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.52\n0.39, 16.1\n0.3\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n89.1\n0.49, 16,218\n0.091\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.08\n0.00, 108\n0.5\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.02\n0.00, 2.15\n0.10\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.39\n0.01, 22.9\n0.7\n\n\nPrior stroke\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n174\n4.16, 7,276\n0.007\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nSmoker\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.88\n0.00, 32,643,666,165\n&gt;0.9\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nVenous Thromboembolism:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nCategories\n\n\n\n\n\n\n\n\n    Atrial Fibrillation without Cancer\n—\n—\n\n\n\n\n    Atrial Fibrillation with Cancer\n1.64\n1.07, 2.52\n0.024\n\n\nAge, y\n0.99\n0.97, 1.00\n0.2\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.12\n0.80, 1.56\n0.5\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.36\n0.50, 3.72\n0.5\n\n\n    Black\n1.47\n0.87, 2.49\n0.2\n\n\n    Hispanic\n1.84\n1.02, 3.31\n0.042\n\n\n    Native American\n1.59\n0.24, 10.7\n0.6\n\n\n    Other\n1.12\n0.37, 3.39\n0.8\n\n\nElixhauser comorbidity index\n1.43\n1.28, 1.60\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.65\n1.06, 2.58\n0.026\n\n\n    $66,000 - $87,999\n1.67\n1.01, 2.76\n0.044\n\n\n    $88,000 or more\n1.18\n0.62, 2.22\n0.6\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.69\n0.29, 1.61\n0.4\n\n\n    Medicare\n0.64\n0.41, 0.99\n0.046\n\n\n    Other\n0.96\n0.32, 2.92\n&gt;0.9\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.91\n0.54, 1.51\n0.7\n\n\n    South\n0.90\n0.60, 1.34\n0.6\n\n\n    West\n1.01\n0.60, 1.69\n&gt;0.9\n\n\nLocation of patient’s residence\n\n\n\n\n\n\n\n\n    Central metro ≥1 million\n—\n—\n\n\n\n\n    Fringe metro ≥1 million\n0.58\n0.36, 0.92\n0.021\n\n\n    Metro 250,000-999,999\n0.76\n0.47, 1.24\n0.3\n\n\n    Metro 50,000-249,999\n1.24\n0.71, 2.15\n0.5\n\n\n    Micropolitan\n0.70\n0.34, 1.41\n0.3\n\n\n    Other\n0.95\n0.49, 1.83\n0.9\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.03\n0.62, 1.71\n&gt;0.9\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.61\n0.41, 0.90\n0.013\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.79\n0.57, 1.11\n0.2\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.03\n0.71, 1.51\n0.9\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.71\n0.44, 1.14\n0.2\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.77\n0.54, 1.11\n0.2\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.60\n0.40, 0.91\n0.015\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.53\n0.37, 0.77\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.53\n0.32, 0.88\n0.013\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.39\n0.18, 0.82\n0.013\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.02\n0.63, 1.63\n&gt;0.9\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.94\n0.56, 1.59\n0.8\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.61\n0.42, 0.90\n0.013\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.63\n0.39, 1.02\n0.061\n\n\nPrior stroke\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.13\n0.75, 1.71\n0.6\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.83\n0.47, 1.45\n0.5\n\n\nSmoker\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.00\n0.00, 0.00\n&lt;0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nMajor bleeding:"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Impact of Malignancy on Vacular Outcomes in Patients with Atrial Fibrillation",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nCategories\n\n\n\n\n\n\n\n\n    Atrial Fibrillation without Cancer\n—\n—\n\n\n\n\n    Atrial Fibrillation with Cancer\n-0.19\n-1.0, 0.62\n0.6\n\n\nAge, y\n-0.01\n-0.03, 0.00\n0.13\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.64\n0.25, 1.0\n0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n-0.42\n-1.5, 0.69\n0.5\n\n\n    Black\n1.1\n0.25, 2.0\n0.012\n\n\n    Hispanic\n0.84\n-0.44, 2.1\n0.2\n\n\n    Native American\n1.3\n-1.4, 4.1\n0.3\n\n\n    Other\n-0.54\n-1.5, 0.46\n0.3\n\n\nElixhauser comorbidity index\n1.4\n1.2, 1.5\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.18\n-0.39, 0.74\n0.5\n\n\n    $66,000 - $87,999\n0.26\n-0.34, 0.85\n0.4\n\n\n    $88,000 or more\n0.04\n-0.59, 0.67\n&gt;0.9\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.52\n-1.1, 2.1\n0.5\n\n\n    Medicare\n0.41\n-0.24, 1.1\n0.2\n\n\n    Other\n1.8\n-0.20, 3.9\n0.077\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.18\n-0.44, 0.80\n0.6\n\n\n    South\n-0.03\n-0.50, 0.44\n&gt;0.9\n\n\n    West\n-0.28\n-1.0, 0.49\n0.5\n\n\nLocation of patient’s residence\n\n\n\n\n\n\n\n\n    Central metro ≥1 million\n—\n—\n\n\n\n\n    Fringe metro ≥1 million\n0.04\n-0.64, 0.72\n&gt;0.9\n\n\n    Metro 250,000-999,999\n-0.10\n-0.72, 0.53\n0.8\n\n\n    Metro 50,000-249,999\n-0.39\n-1.1, 0.36\n0.3\n\n\n    Micropolitan\n-0.44\n-1.2, 0.28\n0.2\n\n\n    Other\n0.21\n-0.54, 0.95\n0.6\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.9\n-2.5, -1.2\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.98\n-1.4, -0.56\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.35\n-0.74, 0.04\n0.076\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.26\n-0.64, 0.12\n0.2\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.6\n-2.1, -1.1\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.91\n-1.4, -0.39\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.1\n-1.7, -0.61\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.2\n-1.7, -0.73\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.0\n-1.5, -0.53\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.31\n-0.78, 1.4\n0.6\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.80\n-1.3, -0.33\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.30\n-1.1, 0.45\n0.4\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.9\n-2.4, -1.3\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.0\n-1.6, -0.41\n&lt;0.001\n\n\nPrior stroke\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.44\n-0.89, 0.02\n0.060\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.81\n-1.2, -0.37\n&lt;0.001\n\n\nSmoker\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.7\n-4.0, 0.64\n0.2\n\n\n\nAbbreviation: CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nCategories\n\n\n\n\n\n\n\n\n    Atrial Fibrillation without Cancer\n—\n—\n\n\n\n\n    Atrial Fibrillation with Cancer\n2,846\n-8,735, 14,427\n0.6\n\n\nAge, y\n-783\n-1,066, -501\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n10,478\n4,248, 16,708\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n14,634\n-9,316, 38,583\n0.2\n\n\n    Black\n-1,008\n-11,602, 9,586\n0.9\n\n\n    Hispanic\n38,933\n10,102, 67,764\n0.008\n\n\n    Native American\n13,343\n-42,300, 68,985\n0.6\n\n\n    Other\n4,814\n-17,532, 27,160\n0.7\n\n\nElixhauser comorbidity index\n15,477\n11,913, 19,041\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1,727\n-7,137, 10,591\n0.7\n\n\n    $66,000 - $87,999\n-3,368\n-11,666, 4,930\n0.4\n\n\n    $88,000 or more\n-2,965\n-14,051, 8,120\n0.6\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n8,174\n-13,292, 29,641\n0.5\n\n\n    Medicare\n9,475\n-683, 19,633\n0.068\n\n\n    Other\n23,623\n-14,223, 61,468\n0.2\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n3,250\n-8,005, 14,505\n0.6\n\n\n    South\n13,128\n4,894, 21,363\n0.002\n\n\n    West\n43,864\n27,556, 60,172\n&lt;0.001\n\n\nLocation of patient’s residence\n\n\n\n\n\n\n\n\n    Central metro ≥1 million\n—\n—\n\n\n\n\n    Fringe metro ≥1 million\n-8,814\n-20,038, 2,410\n0.12\n\n\n    Metro 250,000-999,999\n-5,253\n-21,260, 10,755\n0.5\n\n\n    Metro 50,000-249,999\n-15,651\n-32,034, 733\n0.061\n\n\n    Micropolitan\n-22,846\n-35,907, -9,784\n&lt;0.001\n\n\n    Other\n-19,129\n-31,931, -6,326\n0.003\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-22,263\n-33,913, -10,612\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-13,489\n-20,152, -6,827\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n5,751\n-906, 12,407\n0.090\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n7,730\n269, 15,191\n0.042\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-14,275\n-23,090, -5,459\n0.002\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-20,140\n-29,262, -11,019\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-15,974\n-25,249, -6,699\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-14,450\n-21,855, -7,045\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1,621\n-6,571, 9,813\n0.7\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n3,866\n-11,633, 19,365\n0.6\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-10,138\n-17,967, -2,308\n0.011\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-12,069\n-22,887, -1,251\n0.029\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-21,772\n-33,260, -10,284\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-6,608\n-17,525, 4,309\n0.2\n\n\nPrior stroke\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-13,132\n-19,260, -7,004\n&lt;0.001\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-17,489\n-25,469, -9,510\n&lt;0.001\n\n\nSmoker\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-2,273\n-44,863, 40,316\n&gt;0.9\n\n\n\nAbbreviation: CI = Confidence Interval"
  }
]